Lumos Pharma, Inc. (LUMO)

8.67 +0.27 (+3.27%) At close: 04:00PM EDT

Lumos Pharma, Inc.

4200 Marathon Boulevard
Suite 200
Austin, TX 78756
United States
512 215 2630
https://www.lumos-pharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 29

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard J. Hawkins	CEO & Chairman	950.32k	N/A	1949
Dr. John C. McKew Ph.D.	Chief Scientific Officer & Pres	804.98k	N/A	1964
Ms. Lori D. Lawley CPA	CFO & Principal Accounting Officer	519.11k	N/A	1984
Lisa Miller	Sr. Director of Investor Relations	N/A	N/A	N/A
Mr. Bradley J. Powers J.D.	Chief Compliance Officer & Gen. Counsel	N/A	N/A	1979
Mr. Carl W. Langren	Consultant	N/A	N/A	1955
Mr. Aaron Schuchart B.B.A., CPA, M.B.A.	Chief Bus. Officer	N/A	N/A	1965
Dr. David B. Karpf B.A., M.D.	Chief Medical Officer	N/A	N/A	1955
Mr. Eddie L. Varnado M.B.A.	VP of Fin. & Corp. Controller	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Corporate governance

Lumos Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.